Table 4 Genes whose expressions were negatively correlated with eGFR were also modulated by Ondansetron.
From: Effect of ondansetron on reducing ICU mortality in patients with acute kidney injury
Gene Symbol | Gene title | Correlation of gene mRNA expression with eGFR in human AKI cohort | Gene expression mRNA change in GSE30718 (AKI vs normal control) | Gene expression fold change by Ondansetron treatment | |
|---|---|---|---|---|---|
p value | Fold change | ||||
KPNA2 | Karyopherin a2 (RAG cohort 1, importin a1) | − 0.72 | 6.73E−06 | 1.9 | 1.68 |
CASP1 | Caspase 1, apoptosis-related cysteine | ||||
peptidase (IL-1, b, convertase) | − 0.72 | 1.00E−03 | 2.1 | − 8.03 | |
TFPI | Tissue factor pathway inhibitor (lipoproteinassociated | ||||
coagulation inhibitor) | − 0.7 | 0.01 | 1.5 | 4.25 | |
AMACR | a-methylacyl-CoA racemase | − 0.68 | 2.80E−04 | 2.3 | − 2.38 |
GBP2 | Guanylate binding protein 2, IFN-inducible | − 0.67 | 1.00E−03 | 2.1 | − 4.71 |
MCL1 | Myeloid cell leukemia sequence 1 (BCL2-related) | − 0.66 | 3.90E−05 | 2.8 | − 3.07 |
MET | Met proto-oncogene (hepatocyte growth factor receptor) | − 0.66 | 1.05E−06 | 2.9 | − 2.32 |
CPD | Carboxypeptidase D | − 0.66 | 7.50E−06 | 3.4 | − 2.4 |
